A control comparing APP and phosphorylated tau levels in the hippocampus of 3xTg-AD mice 4 months after injection with AAV-GFP, and uninjected age-matched 3xTg-AD mice showed no difference, indicating that the injection procedure did not enhance AD pathology in these mice (Supplementary Fig. S1B, C). The gene discussed is MAPT; the disease is Alzheimer disease.